TScan Therapeutics Temettü

Temettü kriter kontrolleri 0/6

TScan Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-12.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-12.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: TCRX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: TCRX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

TScan Therapeutics Piyasaya Karşı Temettü Getirisi

TCRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (TCRX)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (TCRX) (3 yıla kadar)	n/a

Önemli Temettü: TCRX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, TCRX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: TCRX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: TCRX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

TScan Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

TScan Therapeutics, Inc Announces Board Changes

Consensus revenue estimates fall by 60%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Tscan Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Tcr-T Therapy for the Treatment of Solid Tumors

TScan Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

TScan Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.084643 million.

TScan Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.084643 million.

TScan Therapeutics, Inc. Announces Executive Changes

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.5% to US$11.40

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. Appoints Jason A. Amello as Chief Financial Officer

Tscan Therapeutics Appoints Jason A. Amello as Chief Financial Officer

Chairman of the Board recently bought US$142k worth of stock

Tscan Therapeutics, Inc. Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 At the 65Th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors

TScan Therapeutics, Inc. Announces Appointment of Justin Mccue, as Chief Technology Officer

New major risk - Share price stability

Consensus revenue estimates decrease by 33%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Tscan Therapeutics, Inc. Announces Management Appointments

New major risk - Financial position

High number of new and inexperienced directors

TScan Therapeutics, Inc. Announces Board Changes

Chairman of the Board recently bought US$100k worth of stock

TScan Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $139.995299 million.

TScan Therapeutics, Inc. Appoints Gavin MacBeath as A Member of the Board of Directors

TScan Therapeutics, Inc. Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Full year 2022 earnings: EPS and revenues miss analyst expectations

TScan Therapeutics, Inc. Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

TScan Therapeutics, Inc. Announces its 2023 Clinical Pipeline Plans

Tscan Therapeutics Presents Phase 1 Umbrella Trial in Progress on Ha-1 (Tsc-100) and Ha-2 (Tsc-101) At the 64Th American Society of Hematology Annual Meeting 2022

Price target decreased to US$14.00

Consensus revenue estimates increase by 19%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

TScan Therapeutics, Inc. Appoints Debora Barton to Serve as Chief Medical Officer, Effective July 5, 2022

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

TScan Therapeutics, Inc. Promotes Gavin Macbeath, Ph.D. to Chief Scientific and Operations Officer

Tscan Therapeutics, Inc. Announces Fda Clearance of Investigational New Drug Application for Tsc-101 for the Treatment of Hematologic Malignancies

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

President recently bought US$90k worth of stock

Consensus revenue estimates increase by 16%

TScan Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Senior VP & CFO recently bought US$51k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

TScan Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

President exercised options to buy US$236k worth of stock.

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

President recently bought US$96k worth of stock

TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin